Vimarsana
Biggest News Aggregation in the World

Page 34 - Linkedin Facebook News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Linkedin Facebook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Linkedin Facebook Today - Breaking & Trending Today

TIAA Applauds Inclusion of SECURE 2.0 Retirement Provisions in Appropriations Package - Vimarsana News

TIAA Applauds Inclusion of SECURE 2.0 Retirement Provisions in Appropriations Package

/PRNewswire/ -- TIAA issued the following statement from Thasunda Brown Duckett, president and CEO, on the inclusion of the provisions from SECURE 2.0 in the...

TIAA Traditional Increases Income Payments by 3% for 2023 - Vimarsana News

TIAA Traditional Increases Income Payments by 3% for 2023

A Fixed Annuity with a Long History of Paying IncreasesNEW YORK, Dec. 19, 2022 /PRNewswire/ -- Beginning in January 2023, income payments to TIAA ...

Revitalist's Kathryn Walker and Awakn's Prof. David Nutt to Host Webinar on Ketamine-Assisted Therapy for Veterans' Suffering With Addictions - Vimarsana News

Revitalist's Kathryn Walker and Awakn's Prof. David Nutt to Host Webinar on Ketamine-Assisted Therapy for Veterans' Suffering With Addictions

19.12.2022 - REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist'' or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), is partnering with Awakn’s Prof. David Nutt to discuss ketamine-assisted therapy for Veterans suffering with Addictions in a live webinar. ...

Awakn Life Sciences Corp.: Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth - Vimarsana News

Awakn Life Sciences Corp.: Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth

And continued successful execution of R&D and Commercialization strategies Toronto, Ontario--(Newsfile Corp. - December 15, 2022) - Awakn Life Sciences Corp.(NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn")

Awakn Life Sciences Corp.: Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service (NHS) - Vimarsana News

Awakn Life Sciences Corp.: Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service (NHS)

Phase III trial confirmed to cost CA$3.75 million, with a UK Government agency funding 66% of this cost Toronto, Ontario--(Newsfile Corp. - December 13, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: